Heart Hospital of New Mexico is the First Hospital to Complete 200 Ventricular Ablation Procedures with the VIVO System
EP Lab Staff

The EP Lab staff celebrating the 200th procedure at Heart Hospital of New Mexico.

FORT MILL, S.C., Aug. 07, 2025 (GLOBE NEWSWIRE) — Catheter Precision, Inc. (VTAK – NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market announced that the Heart Hospital of New Mexico is the first customer to complete 200 ventricular ablation procedures using its VIVO system. Heart Hospital of New Mexico is part of the Lovelace Health system which is made up of five hospitals, 33 health care clinics and seven outpatient therapy clinics with over 300 healthcare providers. The Heart Hospital of New Mexico at Lovelace Medical Center is New Mexico’s only hospital dedicated exclusively to cardiovascular care. David Jenkins, CEO of Catheter Precision said, “We are excited to congratulate the Heart Hospital of New Mexico on celebrating their 200th procedure utilizing VIVO. VIVO is a tool that is designed to help physicians and as one of the first users of VIVO, the physician team has fully embraced the technology. They have published their data and welcomed physicians for educational purposes and their partnership and support of the VIVO product line is invaluable. We look forward to their continued use and seeing what other milestone achievements they accomplish!” About VIVO™ Catheter Precision’s VIVO (View Into Ventricular Onset), is a non-invasive 3D imaging system that enables physicians to identify the origin of ventricular arrhythmias pre-procedure, thereby streamlining workflow and reducing procedure time. VIVO has received marketing clearance from the U.S. FDA and has the CE Mark. About Catheter PrecisionCatheter Precision is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products. Cautionary Note Regarding Forward-Looking StatementsStatements in this press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to substantial risk and uncertainties. Forward-looking statements can be identified by words such as “believe,” “anticipate,” “may,” “might,” “can,” “could,” “continue,” “depends,” “expect,” “expand,” “forecast,” “intend,” “predict,” “plan,” “rely,” “should,” “will,” “may,” “seek,” or the negative of these terms and other similar expressions, although not all forward-looking statements contain these words.  These forward-looking statements include, but are not limited to, statements regarding product evaluations at the hospital, and that the purchase order indicates that the hospital and its staff see the value and benefits that LockeT can bring and expectations regarding LockeT evaluations in the coming weeks. The Company’s expectations and beliefs regarding these matters may not materialize. Actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of uncertainties, risks and changes in circumstances, including but not limited to risks and uncertainties included under the caption “Risk Factors” in the Company’s Form 10-K filed with the SEC and available at www.sec.gov. The forward-looking statements included in this communication are made only as of the date hereof. The Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law. CONTACTS: Investor Relations973-691-2000IR@catheterprecision.com # # #
Attachment

EP Lab Staff

FORT MILL, S.C., July 07, 2025 (GLOBE NEWSWIRE) — Catheter Precision, Inc. (VTAK – NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market announced today that it has received a purchase order from Centre Hospitalier Universitaire (CHU) de Rennes. This is the first purchase order from Universite de Rennes and marks the largest purchase order for the VIVO product line to date.

FORT MILL, S.C., May 01, 2025 (GLOBE NEWSWIRE) — Catheter Precision, Inc. (VTAK – NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market announced that new clinical data about VIVO is available.

Fort Mill, S.C., April 14, 2025 (GLOBE NEWSWIRE) —  Catheter Precision, Inc. (VTAK – NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market announced that it has received a notice of allowance from the US Patent Office of its first patent in the US for its LockeT product, filed in December 2022, for its design of a surgical closure device for orthoscopic entry wounds.